|
1
|
Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M,
Liu L, Liu C, Xu J, Gao YT, Zheng Y, et al: Cancer statistics:
Current diagnosis and treatment of pancreatic cancer in Shanghai,
China. Cancer Lett. 346:273–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long
J, Liu L, Liu C, Xu J, Ni Q, et al: Blood neutrophil-lymphocyte
ratio predicts survival in patients with advanced pancreatic cancer
treated with chemotherapy. Ann Surg Oncol. 22:670–676. 2015.
View Article : Google Scholar
|
|
4
|
Liu C, Lu Y, Luo G, Cheng H, Guo M, Liu Z,
Xu J, Long J, Liu L, et al: Which patients with para-aortic lymph
node (LN16) metastasis will truly benefit from curative
pancreaticoduodenectomy for pancreatic head cancer? Oncotarget.
7:29177–29186. 2016.PubMed/NCBI
|
|
5
|
Wörmann SM, Diakopoulos KN, Lesina M and
Algül H: The immune network in pancreatic cancer development and
progression. Oncogene. 33:2956–2967. 2014. View Article : Google Scholar
|
|
6
|
Curiel TJ, Coukos G, Zou L, Alvarez X,
Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L,
Burow M, et al: Specific recruitment of regulatory T cells in
ovarian carcinoma fosters immune privilege and predicts reduced
survival. Nat Med. 10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Clark CE, Beatty GL and Vonderheide RH:
Immunosurveillance of pancreatic adenocarcinoma: Insights from
genetically engineered mouse models of cancer. Cancer Lett.
279:1–7. 2009. View Article : Google Scholar
|
|
8
|
Xu YF, Lu Y, Cheng H, Shi S, Xu J, Long J,
Liu L, Liu C and Yu X: Abnormal distribution of peripheral
lymphocyte subsets induced by PDAC modulates overall survival.
Pancreatology. 14:295–301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rébé C and Ghiringhelli F: Cytotoxic
effects of chemotherapy on cancer and immune cells: How can it be
modulated to generate novel therapeutic strategies? Future Oncol.
11:2645–2654. 2015. View Article : Google Scholar
|
|
10
|
Bardeesy N and DePinho RA: Pancreatic
cancer biology and genetics. Nat Rev Cancer. 2:897–909. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neoptolemos JP, Stocken DD, Friess H,
Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C,
Lacaine F, et al European Study Group for Pancreatic Cancer: A
randomized trial of chemoradiotherapy and chemotherapy after
resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo G, Long J, Zhang B, Liu C, Xu J, Ni Q
and Yu X: Stroma and pancreatic ductal adenocarcinoma: An
interaction loop. Biochim Biophys Acta. 1826:170–178.
2012.PubMed/NCBI
|
|
13
|
Herbel C, Patsoukis N, Bardhan K, Seth P,
Weaver JD and Boussiotis VA: Clinical significance of T cell
metabolic reprogramming in cancer. Clin Transl Med. 5:292016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Molon B, Calì B and Viola A: T cells and
cancer: How metabolism shapes immunity. Front Immunol. 7:202016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshida N, Kinugasa T, Miyoshi H, Sato K,
Yuge K, Ohchi T, Fujino S, Shiraiwa S, Katagiri M, Akagi Y, et al:
A High RORγT/CD3 ratio is a strong prognostic factor for
postoperative survival in advanced colorectal cancer: Analysis of
helper T cell lymphocytes (Th1, Th2, Th17 and regulatory T cells).
Ann Surg Oncol. 23:919–927. 2016. View Article : Google Scholar
|
|
16
|
Wang WQ, Liu L, Xu HX, Wu CT, Xiang JF, Xu
J, Liu C, Long J, Ni QX and Yu XJ: Infiltrating immune cells and
gene mutations in pancreatic ductal adenocarcinoma. Br J Surg.
103:1189–1199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Antonucci L, Fagman JB, Kim JY, Todoric J,
Gukovsky I, Mackey M, Ellisman MH and Karin M: Basal autophagy
maintains pancreatic acinar cell homeostasis and protein synthesis
and prevents ER stress. Proc Natl Acad Sci USA. 112:E6166–E6174.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Zhu F, Jiang J, Sun C, Zhong Q, Shen
M, Wang X, Tian R, Shi C, Xu M, et al: Simultaneous inhibition of
the ubiquitin-proteasome system and autophagy enhances apoptosis
induced by ER stress aggravators in human pancreatic cancer cells.
Autophagy. 12:1521–1537. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kong B, Wu W, Valkovska N, Jäger C, Hong
X, Nitsche U, Friess H, Esposito I, Erkan M, Kleeff J, et al: A
common genetic variation of melanoma inhibitory activity-2 labels a
subtype of pancreatic adenocarcinoma with high endoplasmic
reticulum stress levels. Sci Rep. 5:81092015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mahalingam D, Patel S, Nuovo G, Gill G,
Selvaggi G, Coffey M and Nawrocki ST: The combination of
intravenous Reolysin and gemcitabine induces reovirus replication
and endoplasmic reticular stress in a patient with KRAS-activated
pancreatic cancer. BMC Cancer. 15:5132015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng S, Swanson K, Eliaz I, McClintick
JN, Sandusky GE and Sliva D: Pachymic acid inhibits growth and
induces apoptosis of pancreatic cancer in vitro and in vivo by
targeting ER stress. PLoS One. 10:e01222702015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ho PC, Bihuniak JD, Macintyre AN, Staron
M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, et al:
Phosphoenolpyruvate is a metaboliccheckpoint of anti-tumor T cell
responses. Cell. 162:1217–1228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Biswas SK: Metabolic reprogramming of
immune cells in cancer progression. Immunity. 43:435–449. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fridman WH, Pagès F, Sautès-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reichert TE, Strauss L, Wagner EM, Gooding
W and Whiteside TL: Signaling abnormalities, apoptosis, and reduced
proliferation of circulating and tumor-infiltrating lymphocytes in
patients with oral carcinoma. Clin Cancer Res. 8:3137–3145.
2002.PubMed/NCBI
|
|
26
|
Fu J, Zhang Z, Zhou L, Qi Z, Xing S, Lv J,
Shi J, Fu B, Liu Z, Zhang JY, et al: Impairment of CD4+
cytotoxic T cells predicts poor survival and high recurrence rates
in patients with hepatocellular carcinoma. Hepatology. 58:139–149.
2013. View Article : Google Scholar
|
|
27
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsuchikawa T, Hirano S, Tanaka E,
Matsumoto J, Kato K, Nakamura T, Ebihara Y and Shichinohe T: Novel
aspects of preoperative chemoradiation therapy improving anti-tumor
immunity in pancreatic cancer. Cancer Sci. 104:531–535. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Homma Y, Taniguchi K, Murakami T, Nakagawa
K, Nakazawa M, Matsuyama R, Mori R, Takeda K, Ueda M, Ichikawa Y,
et al: Immunological impact of neoadjuvant chemoradiotherapy in
patients with borderline resectable pancreatic ductal
adenocarcinoma. Ann Surg Oncol. 21:670–676. 2014. View Article : Google Scholar
|
|
30
|
Bailur JK, Pawelec G, Hatse S, Brouwers B,
Smeets A, Neven P, Laenen A, Wildiers H and Shipp C: Immune
profiles of elderly breast cancer patients are altered by
chemotherapy and relate to clinical frailty. Breast Cancer Res.
19:202017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van Meir H, Nout RA, Welters MJ, Loof NM,
de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ,
et al: Impact of (chemo)radiotherapy on immune cell composition and
function in cervical cancer patients. OncoImmunology.
6:e12670952016. View Article : Google Scholar
|
|
32
|
Tsuchikawa T, Takeuchi S, Nakamura T,
Shichinohe T and Hirano S: Clinical impact of chemotherapy to
improve tumor microenvironment of pancreatic cancer. World J
Gastrointest Oncol. 8:786–792. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamamoto T, Yanagimoto H, Satoi S,
Toyokawa H, Hirooka S, Yamaki S, Yui R, Yamao J, Kim S and Kwon AH:
Circulating CD4+CD25+ regulatory T cells in
patients with pancreatic cancer. Pancreas. 41:409–415. 2012.
View Article : Google Scholar
|
|
34
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Speiser DE, Ho PC and Verdeil G:
Regulatory circuits of T cell function in cancer. Nat Rev Immunol.
16:599–611. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dang EV, Barbi J, Yang HY, Jinasena D, Yu
H, Zheng Y, Bordman Z, Fu J, Kim Y, et al: Control of
TH17/Treg balance by hypoxia-inducible factor
1. Cell. 146:772–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sinclair LV, Rolf J, Emslie E, Shi YB,
Taylor PM and Cantrell DA: Control of amino-acid transport by
antigen receptors coordinates the metabolic reprogramming essential
for T cell differentiation. Nat Immunol. 14:500–508. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang Y, Ma C, Zhang Q, Ye J, Wang F,
Zhang Y, Hunborg P, Varvares MA, Hoft DF, Hsueh EC, et al:
CD4+ and CD8+ T cells have opposing roles in
breast cancer progression and outcome. Oncotarget. 6:17462–17478.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guéry L and Hugues S: Th17 Cell plasticity
and functions in cancer immunity. BioMed Res Int. 2015:3146202015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ivanova EA and Orekhov AN: T Helper
lymphocyte subsets and plasticity in autoimmunity and cancer: An
overview. BioMed Res Int. 2015:3274702015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chaudhary B, Elkord E and Regulatory T:
Regulatory T cells in the tumor microenvironment and cancer
progression: Role and Therapeutic Targeting. Vaccines (Basel).
4:E282016. View Article : Google Scholar
|
|
44
|
Alizadeh D, Katsanis E and Larmonier N:
The multifaceted role of Th17 lymphocytes and their associated
cytokines in cancer. Clin Dev Immunol. 2013:9578782013. View Article : Google Scholar
|
|
45
|
Chaudhry A, Rudra D, Treuting P, Samstein
RM, Liang Y, Kas A and Rudensky AY: CD4+ regulatory T
cells control TH17 responses in a Stat3-dependent manner. Science.
326:986–991. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang X, Wang L, Mo Q, Dong Y, Wang G and
Ji A: Changes of Th17/Treg cell and related cytokines in pancreatic
cancer patients. Int J Clin Exp Pathol. 8:5702–5708.
2015.PubMed/NCBI
|
|
47
|
Gagliani N, Amezcua Vesely MC, Iseppon A,
Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limón P, Paiva RS,
Ching T, et al: Th17 cells transdifferentiate into regulatory T
cells during resolution of inflammation. Nature. 523:221–225. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang G, Li H, Yao Y, Xu F, Bao Z and Zhou
J: Treg/Th17 imbalance in malignant pleural effusion partially
predicts poor prognosis. Oncol Rep. 33:478–484. 2015.
|
|
49
|
Chellappa S, Hugenschmidt H, Hagness M,
Line PD, Labori KJ, Wiedswang G, Taskén K and Aandahl EM:
Regulatory T cells that co-express RORγt and FOXP3 are
pro-inflammatory and immunosuppressive and expand in human
pancreatic cancer. OncoImmunology. 5:e11028282015. View Article : Google Scholar
|
|
50
|
Zou W and Restifo NP: TH17
cells in tumour immunity and immunotherapy. Nat Rev Immunol.
10:248–256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
